In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
It has been about a month since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have added about 6.5% in that time frame, outperforming the S&P 500. But investors have to be ...
Proposed changes to North Carolina's math standards would shake up requirements for upperclassmen in the state’s public high schools and emphasize real-world problem-solving in all grade levels. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback